Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients

Sponsor
AbbVie
Study ID
NCT02739828
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The objective of this study is to assess quality of life (QoL), skin pain, work productivity/activity and health related problems in Swedish patients with moderate to severe HS before and after 6 months treatment with Adalimumab. Participants will be treated in accordance with normal routine clinical care.

Key Dates

Start date
Apr 7, 2016
Status verified
May 2018
Primary completion
Mar 28, 2018
Completion
Mar 28, 2018

Study Design

Enrollment
24 participants (actual)

Arms

  • Arm: Patients with Hidradenitis Suppurativa
    Patients with moderate or severe HS treated prescribed adalimumab according to the Swedish Summary of Product Characteristics and treated as per routine clinical practice.

Primary Outcome Measure

Change From Baseline in DLQI at Week 12 [ Time Frame: Baseline, Week 12 ]

Related Studies